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INTRODUCTION 
Preeclampsia (PE) is a major cause of maternal mortality 
in worldwide which affecting 2 to 8% of all deliveries. 
The prevalence of preeclampsia in pregnancy is 5-8% and 
its incidence is common in nulliparous pregnancy.1,2 
The exact theory and mechanism of pre-eclampsia is still 
unknown. Pre-eclampsia is one of the common disorders 
during pregnancy which had been associated with 
increasing blood pressure in the second half of pregnancy 
and proteinuria. It considered by the World Health 
Organization as one of the women health issues.3  
Usually, PE occur in the second half of pregnancy and is 
known as a systematic disorder which deal to HELLP 
syndrome (hemolysis, elevated liver enzymes and low 
platelet count) and the causes of most cases remains 
unknown.4,5  
Circulating levels of PLGF have been reported to be 
reduced in women with preeclampsia. Based on these 
findings, it was hypothesized that circulating 
PLGF may be a predictor of preeclampsia. Several 
studies with conflicting results have recently been 
published on the predictive value of mid gestational 
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PLGF plasma concentrations in early identification of 
pregnant women at risk of developing preeclampsia.6 
Verlohren et al. reported that the sFlt-1/PLGF ratio is 
important to identify women at risk for delivery and a 
reliable tool to discriminate between different types of 
pregnancy-related hypertensive disorders. In women with 
suspected preeclampsia at < 34 weeks, the circulating 
sFlt1/PLGF ratio predicts adverse outcomes which occur 
within two weeks.7-9 
PLGF is an angiogenic growth factor related to vascular 
endothelial growth factor that is exclusively produced by 
the trophoblast. In normal pregnancy, levels of PLGF 
increase throughout gestation, peaking at approximately 
26–30 weeks. Decreasing levels of PLGF have 
consistently been found throughout gestation and 
associated with pre-eclampsia. PLGF levels have also 
been reported to be low in the first trimester at women 
who subsequently developed preeclampsia compared to 
women with normal pregnancy, despite the suggested 
role of PLGF as a first-trimester predictor of pre-
eclampsia, a recent study using urinary PLGF levels in 
the first trimester failed to confirm this relationship.10-12 
Placental growth factor (PLGF) is a member of the 
vascular endothelial growth factor family and is 
implicated in angiogenesis and trophoblastic invasion of 
the maternal spiral arteries. Maternal serum levels of 
PLGF at 11–13 weeks’ gestation is decreased in 
pregnancies with fetal aneuploidy and those with 
impaired placentation resulting in pre-eclampsia (PE) and 
delivery of small-for-gestational-age (SGA) neonates. 
Serum levels of PLGF are also reduced in the second and 
third trimesters of pregnancies that develop PE or deliver 
SGA neonates.7,13-23 
While the pathophysiology of preeclampsia is not yet 
fully understood, there is growing evidence associating 
angiogenic proteins in screening, diagnosing and 
predicting the clinical course of the condition.8,10,24,25 
Placental growth factor (PLGF) is a proangiogenic 
marker that circulates at high concentrations in normal 
pregnancies. In pregnancies complicated by 
preeclampsia, circulating levels of unbound PLGF are 
decreased.2,3  
METHODS 
A case-control study was conducted on 30 women with 
suspected preeclampsia and 101 healthy pregnant women 
in the gestational age 20 to 40 weeks which selected 
randomly of women who visited a specialized clinic. The 
patients who have read and signed the consent form, 
entered the study. The two groups were similar in their 
job, weight, education, drug misusage, social and 
economic status and gestational age. Pre-eclampsia was 
defined as BP ≥160 mmHg systolic and/or ≥110 mmHg 
diastolic (on 2 occasions at least 6 hours apart, while the 
patient is on bed rest) and proteinuria is 300 mg/24 hours; 
or ≥1+ (on 2 random urine samples, collected at least 4 
hours apart); or protein: creatinine ratio is ≥0.3 mg/dL. 
The inclusion criteria were to have the age between 15 
and 35, Singleton pregnancy, no history of gestational 
diabetes and lack of kidney issues during the current 
pregnancy. All women in two groups were followed until 
the end of the pregnancy and at the end, in terms of 
pregnancy (gestational age, type of delivery and 
neonate’s birth weights) were studied. Of the women, an 
interview was taken by a checklist and pre-eclampsia was 
followed by clinical tests and examination. 2 cc of blood 
was taken of the women in two groups and after 
extracting the serum, the samples were restored in 
temperature of minus 20 0C and then, end of sampling, 
Placental growth factor assay was done by ELISA kit 
Cusabio. China CSB-EO470. Collected data were 
analyzed by statistical methods in SPSS.16.  
RESULTS 
The mean gestational age in the preeclampsia women was 
33.7 and in healthy women was 33.3 weeks (P= 0.035). 
There was significant difference between two groups in 
term of characterized such as age, HR, Systolic and 
Diastolic Blood Pressure (Table 1). 
Table 1: Characteristics of study population in two 
groups. 
Characteristics 
of study 
population  
Healthy 
women 
Preeclamptic 
women  
p-
value 
Gestational age  33.4±4.4 33.7±3.75 0.035 
Age  28.4±4.4 30±4.4 0.03 
Height  1.62±0.5 1.61±0.7 0.25 
Weight  70.5±12.8 72±10.3 0.26 
Weight in 
pregnancy time 
78.3±10.3 81.5±13 0.06 
BT 36.9±0.24 36.8±0.3 0.4 
HR 72.8±18.4 79±5.7 0.03 
BP Systolic 
(mmHg) 
106±7.8 122±19.7 0.001 
BP Diastolic 
(mmHg) 
68.1±5.9 75±13.6 0.001 
In the preeclampsia women, most of patients due to high 
blood pressure and in healthy women due to childbirth 
pain had come to the clinic.  
There was significant difference between two groups in 
term of pregnancy outcomes such as mode of delivery, 
termination age of pregnancy, birth weight and 
hospitalization due to pregnancy side-effects (Table 2). 
The PLGF serum level in the preeclamptic women with 
68.1 pg/mL was significantly lower than the healthy 
women with 268.9 pg/mL and in healthy women, 82.2% 
and in preeclamptic women 73.3% had PLGF (between 
12-5th centile) (Table 3). 
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Table 2: Pregnancy outcomes. 
Pregnancy 
outcome 
Healthy 
women 
N=101 
Preeclamptic 
women 
N=30  
p-
value 
Mode of delivery    
0.001  Vaginal 52.5  96.7 
Cesarean Section 47.5 3.3 
Termination age of pregnancy  
 
0.001 
Pre-mature 
preterm birth 
0 13.3 
Post-mature 
preterm 
2.7 60 
Term birth 76.3 26.7 
Birth weight (g)    
0.001 
<1500 9.9 26.7 
1500-2500 0 13.3 
>2500 90.1 60 
HELLP Syndrome (%) 
0.12 Yes 0 3.9 
No 100 96.1 
Hospitalizaton 
because of 
neonatal problems 
(side-effects) (%) 
21.8 66.7 0.001 
Table 3: PLGF levels in two groups. 
PLGF 
values 
(pg/mL) 
healthy 
pregnant 
women 
women with 
suspected pre-
eclampsia  
p-
value  
n % n % 
<12 pg/ml 
(very low)  
- - 2 6.7 0.001 
12 pg/ml-5th 
centile (low) 
18 17.8 22 73.3 
>5th centile 
(Normal) 
83 82.2 6 20 
Total PLGF 268.9±23.2 68.12±11.4 0.001 
In the pre-eclampsia women who had premature preterm, 
50% had PLGF low than 12 pg/mL and in mothers with 
cesarean delivery, 72.4% of and in mothers had babies 
more than 2500 gr, 75% and in mothers had pregnancy 
side-effects, 50% had PLGF in ranged 12 to 5th centile. 
(Table 4). 
DISCUSSION 
In the study of Maynard and et al that was done to 
analyze the serum level of PLGF in the second trimester 
of pregnancy in order to predict pre-eclampsia, 61 
pregnant mothers with the gestational age of 15-18 weeks 
were followed and studied that 11.4% were diagnosed 
with pre-eclampsia which PLGF level in these patients 
were significantly low which in line with our study 
results. The difference in the incidence rate of pre-
eclampsia in two studies can be related to selected study 
population.26 The results of this study showed that 96.8% 
of the mothers in the preeclamptic women and 53% of the 
control group had cesarean that this rate was statistically 
significant between two groups (P=0.001). 
Table 4: PLGF values by pregnancy outcome in 
preeclamptic women. 
PLGF 
values 
Pregnancy 
outcome 
<12 
pg/ml 
(very 
low) 
n(%) 
12 pg/ml-
5th 
centile 
(low) 
n(%) 
>5th 
centile 
(normal) 
n(%) 
p-
value 
Mode of delivery  
0.88 
Vaginal - 1(100) - 
Cesarean 
Section 
2(6.7) 21(72.4) 6(20.8) 
Termination age of pregnancy  
0.001 
Chronic 
Pre-mature 
preterm  
2(50) 2(50) - 
Post-
mature 
preterm 
- 8(100) - 
Term  - 12(66.7) 6(33.3) 
Birth weight (g) 
0.04 
<1500 2(25) 6(75) - 
1500-2500 - 4(100) - 
>2500 - 12(66.7) 6(33.3) 
Pregnancy Side effects  
0.001 Yes 2(50) 2(50) - 
No - 20(76.9) 6(23.1) 
In Gullai and et al study the results revealed that all of the 
blood pressure types, PLGF was notably lower than 
control group and lower PLGF test was the predictor of 
preterm birth.27 In the preeclamptic women, 7.2% of the 
mothers had babies under the weight of 1500 gr, 9.28% 
of the babies were 1500-2500 gr and 88.35% of the 
babies were over 2500 gr which on the aspect of 
birthweight there was a significant difference between 
two groups (P=0.02). 
In 21.4% of the preeclamptic women and 23.3% of the 
control group, babies were hospitalized after birth which 
was no significant difference between two groups. The 
analysis of PLGF serum level in the studied patients 
showed that in mothers diagnosed with pre-eclampsia the 
average PLGF serum level is 71.51 that varies from 11.31 
to 226.71. In healthy mothers the average of PLGF was 
272.11 which is variant from 16.92 to 1552.7. There was 
a significant difference in serum level of pregnant women 
who are diagnosed to pre-eclampsia and the ones that are 
not (P=0.000). In Rana and et al (2012) study, PLGF 
level and sFLt 1 in pre-eclampsia patients was abnormal 
compared to the control group but in comparison of sever 
and mild pre-eclampsia patients only the level of PLGF 
had significant difference.21 The rate of PLGF in blood is 
reduced before the onset of symptoms in 9 to 11 weeks 
and this is in a way that this level notably decreases 5 
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weeks before the increment of blood pressure and 
proteinuria.13 
The analysis of normal and abnormal level of PLGF 
reveal that in mother diagnosed with pre-eclampsia, 
70.4% and in mothers without pre-eclampsia 24% have 
PLGF of 12-100 and none of them had PLGF under 12. 
The results of this study have revealed that all of the 
mothers diagnosed with pre-eclampsia who had 
premature preterm birth, had abnormal PLGF. In the 
mothers diagnosed with pre-eclampsia who had term 
pregnancy, 100% had PLGF of between 12 and 5th centile 
(abnormal). In the study of Gullai and et the results 
showed that in all types of blood pressure types in 
pregnancy, PLGF was notably lower than control group 
and positive PLGF test predicts preterm childbirth in 
women diagnose with pre-eclampsia in Vrlohream's study 
it was revealed that the time between diagnosis to 
pregnancy completion among pre-eclamptic women with 
high sFLt/PLGF ratio had notably decreased.7,27 In the 
study of Chappell and et al, it was determined that PLGF 
is valuable in managing of pregnant mothers suspicious 
to pre-eclampsia especially preterm. Low levels of PLGF 
(under 100 pg/ml) has high sensitivity and negative 
predictive value in determining the pregnant women who 
need pregnancy completion in 14 days due to pre-
eclampsia which was similar to our study results.23 
The analysis of serum level of PLGF in preeclamptic 
mothers with cesarean childbirth showed that 7.4% had 
PLGF of 12 and 70.4% had PLGF of 12-5th centile 
(abnormal) and 22.2% had PLGF of over 5th centile 
(normal). 
The relation between serum level of PLGF and 
birthweight of babies in pregnant mothers diagnosed with 
pre-eclampsia showed that all of mothers who have 
babies under 1500 gr, have abnormal PLGF (28.6% under 
12 and 71.4% PLGF between 12 and 5th centile). In 
preeclamptic mothers who had babies from 1500 to 2500 
grams, all have PLGF between 12 and 5th centile 
(abnormal) and in preeclamptic mothers who had babies 
over 2500 grams, 64.7% have PLGF of 12 to 5th centile 
(abnormal) and 35.3% had normal PLGF. 
Some studies have demonstrated that PLGF 
concentrations begin to decrease from 9-11weeks before 
the onset of preeclampsia, with greatest reductions during 
the 5 weeks before the onset of hypertension or 
proteinuria. Also, Aljebory and et al in a study showed 
that utility of PLGF as an accurate and specific marker 
identifying the underlying cause of disease, placental 
dysfunction is supported by evidence which was in line 
with our study results.28 
CONCLUSION 
Study findings identified PLGF as an ideal, simple and 
non-invasive marker for primary screening at prenatal 
care for women at risk of pre-eclampsia. Also, in 
conclusion, we found that when women were evaluated 
for preeclampsia, the PLGF concentration exactly could 
predict adverse outcomes particularly among women 
have <34 WG, and is a good test or marker for 
management of women with preeclampsia. So, doing 
more studies in this regard in more sample is essential in 
future. 
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